{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:33:17Z","timestamp":1781713997565,"version":"3.54.5"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The World Health Organisation (WHO) recently released the Global Traditional Medicine Strategy 2025\u20132034, calling for strengthened evidence, governance, and integration of safe, effective traditional and complementary practices into national health systems. In oncology, integrative oncology (IO) combines evidence-informed complementary and traditional modalities with standard cancer care to improve symptom control, quality of life, and patient-centred outcomes. Although clinical benefits are increasingly recognised, comprehensive economic evidence remains limited, constraining reimbursement and policy implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review synthesised cost-effectiveness analyses of IO interventions and evaluated their implications for sustainable cancer care within the WHO Traditional, Complementary and Integrative Medicine (TCIM) framework. Searches of PubMed, EMBASE, PsycINFO, EconLit, and CINAHL identified peer-reviewed CEAs, cost-utility, or cost\u2013benefit studies comparing IO with conventional oncology care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten studies met inclusion criteria, comprising six randomised controlled trials, three real-world data analyses, and one model-based evaluation from Europe, Australia, Asia, and the United States. Interventions included psychological, phytotherapeutic, rehabilitative, and mind\u2013body programmes. Across all modalities, IO interventions were either dominant or cost-effective within national willingness-to-pay thresholds. Methodological quality was high (mean CHEERS score 93%), although few studies addressed longterm outcomes, structural uncertainty, or equity impacts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Overall, IO approaches showed favourable or dominant cost-effectiveness with phytotherapeutic and mind\u2013body interventions revealing the most favourable cost-effectiveness profiles, followed by rehabilitative and psychological programmes economic results. As cost-effectiveness analyses are not yet available for all integrative oncology modalities, this systematic review represents an initial synthesis; the findings indicate a consistent trend towards cost-effectiveness, while generalisability across all IO approaches remains to be established. These findings align with the priorities of the WHO Global Traditional Medicine Strategy 2025\u20132034 and suggest that integrative oncology may support patient-centred, sustainable, and culturally sensitive cancer care, potentially supporting its value-based integration into national reimbursement frameworks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251019386<\/jats:ext-link>\n                      , CRD4201019386.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1773455","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:59:33Z","timestamp":1773817173000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of integrative oncology for sustainable and patient-centred cancer care: a systematic review in the context of the WHO global traditional medicine strategy 2025\u20132034"],"prefix":"10.3389","volume":"14","author":[{"given":"Friedemann","family":"Schad","sequence":"first","affiliation":[{"name":"Research Institute Havelh\u00f6he","place":["Berlin, Germany"]},{"name":"Interdisciplinary Oncology and Palliative Care, Hospital Gemeinschaftskrankenhaus Havelh\u00f6he","place":["Berlin, Germany"]},{"name":"Charit\u00e9 Competence Center for Traditional and Integrative Medicine (CCCTIM), Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Thronicke","sequence":"additional","affiliation":[{"name":"Research Institute Havelh\u00f6he","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reinhold","sequence":"additional","affiliation":[{"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Institute for Social Medicine and Health Economics","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiao Li","family":"Oei","sequence":"additional","affiliation":[{"name":"Research Institute Havelh\u00f6he","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Boujnah","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Competence Center for Traditional and Integrative Medicine (CCCTIM), Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Baldini","sequence":"additional","affiliation":[{"name":"EUROCAM","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sz\u0151ke","sequence":"additional","affiliation":[{"name":"International Federation of Anthroposophic Medical Associations (IVAA)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Fuller-Shavel","sequence":"additional","affiliation":[{"name":"Synthesis Clinic","place":["Berkshire, United Kingdom"]},{"name":"NCIO (National Centre for Integrative Oncology)","place":["Berkshire, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Seifert","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Competence Center for Traditional and Integrative Medicine (CCCTIM), Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1089\/jicm.2025.0049","article-title":"Bridging borders in integrative oncology: a global initiative by the Society for Integrative Oncology","volume":"31","author":"Stylianou","year":"2025","journal-title":"J Integr Complement Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgx012","article-title":"A comprehensive definition for integrative oncology","volume":"52","author":"Witt","year":"2017","journal-title":"J Natl Cancer Inst Monogr"},{"key":"ref4","volume-title":"WHO Traditional, Complementary and Integrative Medicine Strategy 2025\u20132034","year":"2024"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e001046","DOI":"10.1136\/bmjopen-2012-001046","article-title":"Are complementary therapies and integrative care cost-effective? A systematic review of economic evaluations","volume":"2","author":"Herman","year":"2012","journal-title":"BMJ Open"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000450645","article-title":"Economic evaluation of complementary and alternative medicine in oncology: is there a difference compared to conventional medicine?","volume":"26","author":"Huebner","year":"2017","journal-title":"Med Princ Pract"},{"key":"ref7","volume-title":"Cost-Effectiveness and cost-Utility of Complementary and Integrative Medicine Compared to Alternative, Traditional or Conventional Medicine Alone in Low- and Middle-Income Countries (LMIC): a systematic Review Protocol","author":"Sirur","year":"2024"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.eujim.2011.06.005","article-title":"Integrative and complementary medicine among cancer patients: a review of the evidence and costs","volume":"37","author":"Jatoi","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1089\/acm.2018.0155","article-title":"The Problematic Economics of Integrative Oncology","volume":"24","author":"Herman","year":"2018","journal-title":"J Altern Complement Med."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/0272989X15583266","article-title":"Distributional cost-effectiveness analysis: a tutorial","volume":"36","author":"Asaria","year":"2016","journal-title":"Med Decis Mak"},{"key":"ref11","author":"Schad","year":"2025"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022)","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3543568","DOI":"10.1155\/2020\/3543568","article-title":"Cost-effectiveness of real-world administration of concomitant Viscum album L. therapy for stage IV pancreatic cancer","volume":"2020","author":"Thronicke","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref14","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 6.4 (Updated August 2023)","author":"Higgins","year":"2023"},{"key":"ref15","year":""},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e0236426","DOI":"10.1371\/journal.pone.0236426","article-title":"Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy in stage IV NSCLC patients","volume":"15","author":"Thronicke","year":"2020","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"ref18","volume-title":"EndNote 21, Reference Management Software","year":"2023"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40258-023-00803-x","article-title":"A model-based estimate of the cost-effectiveness threshold in Germany","volume":"21","author":"Gandjour","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"ref21","year":""},{"key":"ref22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","article-title":"Mapping to estimate health-state utility from non\u2013preference-based outcome measures: an ISPOR good practices for outcomes research task force report","volume":"20","author":"Wailoo","year":"2017","journal-title":"Value Health"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"ref24","volume-title":"Health Technology Evaluation Manual (Methods and Processes; Updated 2022)","year":"2022"},{"key":"ref25","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2022"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14737167.2016.1246961","article-title":"How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 2\/3)","volume":"16","author":"Wijnen","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1378483","DOI":"10.3389\/fphar.2024.1378483","article-title":"Survival and cost-effectiveness analysis of adjunctive Chinese medicine therapy for patients with non-small cell lung cancer: a nationwide cohort study in Taiwan","volume":"15","author":"Tang","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.3802\/jgo.2021.32.e92","article-title":"Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis","volume":"32","author":"Dholakia","year":"2021","journal-title":"J Gynecol Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ejon.2014.04.008","article-title":"Positive and cost-effectiveness effect of spa therapy on resumption of occupational and non-occupational activities in women in breast cancer remission: a French multicentre RCT","volume":"18","author":"Mourgues","year":"2014","journal-title":"Eur J Oncol Nurs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s12913-014-0558-5","article-title":"A cost-utility analysis of a rehabilitation service for people living with and beyond cancer: a randomised wait-list controlled trial in a hospice day care unit","volume":"14","author":"Round","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17260","article-title":"The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: ANCHoR randomised trial","volume":"17","author":"Molassiotis","year":"2013","journal-title":"Health Technol Assess"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e6243","DOI":"10.1002\/pon.6243","article-title":"Cost-utility analysis of a telehealth psychological support intervention for people with primary brain tumour","volume":"33","author":"Gordon","year":"2024","journal-title":"Psycho-Oncology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/pon.5056","article-title":"ConquerFear research group. Cost-effectiveness of an intervention to reduce fear of cancer recurrence: The ConquerFear randomized controlled trial.","volume":"28","author":"Shih","year":"2019","journal-title":"Psycho Oncology."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.2007.14.0822","article-title":"Economic evaluation alongside a clinical trial of psycho-educational interventions to improve adjustment to survivorship among patients with breast cancer","volume":"26","author":"Mandelblatt","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/ijerph17041171","article-title":"Economic evaluations informed exclusively by real world data: a systematic review","volume":"17","author":"Parody-R\u00faa","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13561-022-00390-y","article-title":"Harmonization issues in unit costing of service use for multi-country, multi-sectoral health economic evaluations: a scoping review","volume":"12","author":"Fischer","year":"2022","journal-title":"Heal Econ Rev"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","article-title":"What is real-world data? A review of definitions based on literature and stakeholder interviews","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12906-020-03013-3","article-title":"Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis","volume":"20","author":"Loef","year":"2020","journal-title":"BMC Complement Med Ther"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1200\/JCO.2010.29.5618","article-title":"Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care","volume":"28","author":"Bruera","year":"2010","journal-title":"J Clin Oncol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/pmrj.12552","volume":"13","author":"Chang","year":"2021","journal-title":"Patient and Provider-Reported Satisfaction of Cancer Rehabilitation Telemedicine Visits During the COVID-19 Pandemic."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3322\/caac.21706","article-title":"Integrative oncology: addressing the global challenges of integrative cancer care","volume":"72","author":"Mao","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s40273-021-01094-7","article-title":"Incorporating equity in cost-effectiveness analysis: updated ISPOR recommendations","volume":"26","author":"Asaria","year":"2023","journal-title":"Value Health"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"key":"ref47","volume-title":"Handbooks in Health Economic Evaluation","author":"Cookson","year":"2020"},{"key":"ref48","volume-title":"Making Fair Choices on the Path to Universal Health Coverage","year":"2014"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10389-010-0315-0","article-title":"Economic analysis based on multinational studies: methods for adapting findings to national contexts","volume":"18","author":"Reinhold","year":"2010","journal-title":"J Public Health"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/cpt.857","article-title":"When and how can real-world data analyses substitute for randomized controlled trials?","volume":"102","author":"Franklin","year":"2017","journal-title":"Clin Pharmacol Therapeutics"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1773455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:32:08Z","timestamp":1777476728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1773455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":50,"alternative-id":["10.3389\/fpubh.2026.1773455"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1773455","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1773455"}}